Autohaemotherapy, involving bland treatment ex vivo of blood with ozone and prompt reinfusion into the donor, is a procedure mainly performed in central Europe, which is claimed to have therapeutic value in circulatory disorders, viral diseases and cancer. This practice is mostly performed in private clinics, and good clinical trials have not been published, which has understandably given rise to prejudice and scepticism. By analysing possible mechanisms of action and current hypotheses, this report attempts to explain how this procedure can be useful in such disparate diseases. The current state of the art is presented objectively, the lack of toxicity is documented, and the rationale and therapeutic advantages are discussed, with the aim of eliciting interest in carrying out controlled clinical trials.
JacobsMTh-Untersuchung über Zwischerfdlle und Typische Komplikationen in der Ozon. Sauerstoff Therapie. Ozonnachrichten1986; 5: 1–5.
2.
MattassiR (ed): Ozonoterapia.Milano: Organizzazione Editoriale Medico Scientifica, 1985; pp. 1–179.
3.
RillingSViebahnR (ed): The Use of Ozone in Medicine, 2nd edn.Heidelberg: Haug K.F. Publ., 1987; pp. 1–187.
4.
GarberGECameronDWHawley-FossNThe use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS1991; 5: 981–984.
5.
KonradHOzone therapy for viral diseases. In: Proceedings 10th Ozone World Congress 19–21 March 1991, Monaco.Zurich: International Ozone Association, 1991; pp. 75–83.
6.
RokitanskyOKlinik und Biochemie der Ozontherapie. Hospitalis1982; 52: 643–647.
7.
Riva SanseverinoEMeduriRAPizzinoAEffects of oxygen–ozone therapy on age-related degenerative retinal maculopathy. Panminerva Med1990; 32: 77–84.
8.
WerkmeisterHThe efficacy of O2/O3 low-pressure application in badly healing wounds. In: Proceedings 10th Ozone World Congress 19 – 21 March 1991, Monaco.Zurich: International Ozone Association, 1991; pp 41–53.
9.
LippmanMHealth effects of ozone, a critical review. J Am Air Pollut Control Ass1989; 39: 672–695.
10.
EditorialOzone: too much in the wrong place. Lancet1991; 338: 221–222.
11.
BocciVPaulesuLStudies on the biological effects of ozone: 1. Induction of interferon gamma on human leucocytes. Haematologica1990; 75: 510–515.
12.
PaulesuLLuzziEBocciVStudies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF-α) on human leucocytes. Lymphokine Cytokine Res1991; 5: 409–412.
13.
BocciVLuzziECorradeschiFStudies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res1993; 12: 121–126.
14.
BocciVOzonization of blood for the therapy of viral diseases and immunodeficiences. A hypothesis. Med Hypotheses1992; 39: 30–34.
15.
ViebahnRThe biochemical process underlying ozone therapy. Ozonnachrichten1985; 4: 21–29.
16.
WashuttlJViebahnRSteinerIImmunological examinations in patients with chronic conditions under administration of ozone/oxygen mixtures. Ozone Sci Engin1989; 11: 411–417.
17.
BuckleyRDHackneyJDClarkKOzone and human blood. Arch Environ Health1975; 30: 40–43.
18.
Van der ZeeJTijssen-ChristianseKDubbelmanTMARThe influence of ozone on human red blood cells. Comparison with other mechanisms of oxidative stress. Biochim Biophys Acta1987; 924: 111–118.
19.
HalliwellBGutteridgeJMCThe antioxidants of human extracellular fluids. Arch Biochem Biophys1990; 280: 1–8.
20.
GoldsteinBDBalchumOJEffect of ozone on lipid peroxidation in the red blood cell. Proc Soc Exp Biol Med1967; 126: 356–359.
21.
BocciVDeterminants of erythrocyte ageing: a reappraisal. B J Haematol1981; 48: 515–522.
22.
HalliwellBGutteridgeJMCCrossCEFree radicals, antioxidants, and human disease: where are we now?J Lab Clin Med1992; 119: 598–620.
23.
HnochHGRoschkeWKlugWOzone/Oxygen therapy in proctology. Ozonnachrichten1987; 56: 51–70.
24.
KnochHGKlugWOzon-Sauerstoff-Therapie der proktitis. Die Medizinische Welt1990; 41: 371–374.
25.
CarpendaleMTGriffissJIs there a role for medical ozone in the treatment of HIV and associated infections? In: Ozone in Medicine. Proceedings of the Eleventh Ozone World Congress, August 29 – September 3, 1993, San Francisco, CA, USA. New York: Port City Press, 1993; pp M-1-32 – M-1-45.
26.
ForresterTRelease of ATP from heart. Presentation of a release model using human erythrocyte. In: Biological Actions of Extracellular ATP (DubyakGRFedanJS eds). New York: Annals of the New York Academy of Sciences, 1990; pp 335–352.
27.
ChaudryJHUse of ATP following shock and ischemia In: Biological Actions of Extracellular ATP (DubyakGRFedanJS eds). New York: Annals of the New York Academy of Sciences, 1990; pp 130–141.
28.
AkeyDWaltonTELiquid-phase study of ozone inactivation of Venezuelan Equine Encephalomyelitis virus. Appl Environ Microbiol1985; 50: 882–886.
29.
CarpendaleMTFFreebergJKOzone inactivates HIV at non cytotoxic concentrations. Antiviral Res1991; 16: 281–292.
30.
WellsKHLatinoJGavalchinJInactivation of human immunodeficiency virus type 1 by ozone in vitro. Blood1991; 78: 1882–1890.
31.
NovogrodskyAStenzelKHRubinALStimulation of human peripheral blood lymphocytes by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin: differential effects of adherent cells. J Immunol1977; 118: 852–857.
32.
DianzaniFMonahanTSantianoMMechanism of induction of gamma interferon. Texas Rep Biol Med1981 – 1982; 41: 99–107.
33.
MaruchaPTZeffRAKreutzerDLCytokine induced IL-1β gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. J Immunol1991; 147: 2603–2608.
34.
KitaHOhnishiTOkuboYGranulocyte/macrophage colony stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med1991; 174: 745–756.
35.
MelaniCMattiaGFSilvaniAInterleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. Blood1993; 81: 2744–2749.
36.
BazzoniFCassatellaMARossiFPhagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med1991; 173: 771–780.
37.
DubravekDBSpriggsDRMannickJACirculating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor α. Proc Natl Acad Sci USA1990; 87: 6758–6762.
38.
WongDTWElovicAMatossianKEosinophils from patients with blood eosinophilia express transforming growth factor β1. Blood1991; 78: 2702–2710.
39.
FraserJDStrausDWeissASignal transduction events leading to T-cell lymphokine gene expression. Immunol Today1993; 14: 357–362.
40.
BocciVLuzziECorradeschiFStudies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy. Biotherapy1994; (in press).
41.
TowbinHSchmitzAJakschiesDA whole blood immunoassay for the interferon-inducible human Mx protein. J Interferon Res1992; 12: 67–74.
42.
BocciVLuzziECorradeschiFStudies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. J Biol Regul Homeost Agents1994; (in press).
43.
MosmannTRapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods1983; 65: 55–63.
44.
PetersonMLHarderSRummoNEffect of ozone on leukocyte function in exposed human subjects. Environ Res1978; 15: 485–493.
45.
DziedzicDWhiteHJT-cell activation in pulmonary lymph nodes of mice exposed to ozone. Environ Res1986; 41: 610–622.
46.
DziedzicDWhiteHJResponse of T-cell-deficient mice to ozone exposure. J Toxicol Environ Health1987; 21: 57–71.
47.
BeckerSJordanRLOrlandoGSIn vitro ozone exposure inhibits mitogen-induced lymphocyte proliferation and IL-2 production. J Toxicol Environ Health1989; 26: 469–483.
48.
FujimakiHImpairment of humoral immune responses in mice exposed to nitrogen dioxide and ozone mixtures. Environ Res1989; 48: 211–217.
49.
FreemanBAMuddJBReaction of ozone with sulfhydryls of human erythrocytes. Arch Biochem Biophys1981; 208: 212–220.
50.
ChowCKTappelALActivities of pentose shunt and glycolytic enzymes in lungs of ozone-exposed rats. Arch Environ Health1973; 26: 205–208.
PopovskyMAChaplinHCJr.MooreSBTransfusion-related acute lung injury: a neglected, serious complication of haemotherapy. Transfusion1992; 32: 589–592.
53.
LevineASSivulichMWiernikPHInitial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res1979; 39: 1645–1650.
54.
MacKensenAGalanosCEngelhardtRTreatment of cancer patients with endotoxin induces release of endogenous cytokines. Pathobiology1991; 59: 264–267.
55.
FaradjiABohbotAFrostHPhase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol1991; 9: 1251–1260.
56.
WestermannJPabstRDistribution of lymphocyte subsets and natural killer cells in the human body. Clin Investigator1992; 70: 539–544.
57.
BocciVRoles of interferon produced in physiological conditions. A speculative review. Immunology1988; 64: 1–9.
58.
BocciVTumor therapy with biological response modifiers. Why is progress slow?J Immunology Immunopharmacology1990; 10: 79–82.
59.
RosenbergSALotzeMTMuleJJNew approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med1988; 108: 853–864.
